NCT03517488

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Xencor, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Conditions

• Melanoma
• Breast Carcinoma
• Hepatocellular Carcinoma
• Urothelial Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Renal Cell Carcinoma
• Colorectal Carcinoma
• Non-small Cell Lung Carcinoma
• Gastric or Gastroesophageal Junction Adenocarcinoma
• Endometrial Carcinoma
• Mesothelioma
• Neuroendocrine Carcinoma
• Cervical Cancer
• Small Cell Lung Carcinoma
• Squamous Cell Carcinoma of the Anus
• Castration-Resistant Prostate Carcinoma
• Nasopharyngeal Carcinoma
• Cholangiocarcinoma
• Basal Cell Carcinoma
• Ovarian Carcinoma
• Fallopian Tube Carcinoma
• Thymoma
• Thymic Carcinoma
• Squamous Cell Carcinoma of the Penis
• Vulvar Carcinoma
• Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
• Malignant Adnexal Neoplasms
• Non-squamous Cell Salivary Gland Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	XmAb20717	Monoclonal bispecific antibody

Timeline

• Start date: 2018-07-10
• Primary completion: 2022-06-01
• Completion: 2022-09-06
• First posted: 2018-05-07
• Last updated: 2022-12-01

Locations

17 sites across 1 country: United States

Regulatory

• FDA-regulated drug study